Stay updated on Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%
- Check14 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations related to cancer treatment, while removing several specific terms and references to previous content, particularly in the area of cancer types and drug classifications.SummaryDifference3%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check42 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference1%
- Check49 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
Stay in the know with updates to Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page.